Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 35

Results For "Institute"

942 News Found

Cupid strengthens board with appointment of four new directors
People | December 31, 2024

Cupid strengthens board with appointment of four new directors

Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director


Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’
News | December 20, 2024

Kenvue India presents report on ‘The Hydration Gap for Non-Diarrheal Illnesses’

The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery


Kiran Mazumdar-Shaw honored by ISQ with ‘Jamsetji Tata Award’ for pioneering biosciences movement
News | December 16, 2024

Kiran Mazumdar-Shaw honored by ISQ with ‘Jamsetji Tata Award’ for pioneering biosciences movement

Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International


Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care
News | December 16, 2024

Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care

Harnessing advanced data analysis for early detection, prevention and better outcomes


Pfizer announces Phase 3 PATINA study in patients with HR+, HER2+ metastatic breast cancer
News | December 13, 2024

Pfizer announces Phase 3 PATINA study in patients with HR+, HER2+ metastatic breast cancer

IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy


Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial
Clinical Trials | December 12, 2024

Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial

First and only PARP inhibitor to improve overall survival in early breast cancer


Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million
News | December 09, 2024

Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million

This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape


Emcure and MS Dhoni drive India’s fight against Anemia
Healthcare | November 21, 2024

Emcure and MS Dhoni drive India’s fight against Anemia

Emcure has launched an awareness campaign to help spread the word about male anemia


Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development
People | November 21, 2024

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development

Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer